Rapport Therapeutics (NASDAQ:RAPP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Assessing Rapport Therapeutics (RAPP) Valuation After Recent Share Price Strength [Yahoo! Finance]
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? [Yahoo! Finance]
Rapport Therapeutics (NASDAQ:RAPP) was given a new $51.00 price target on by analysts at Wells Fargo & Company.